NEW YORK (GenomeWeb News) – Nanosys today said that it has licensed patents and patent applications covering the use of nanowires for biosensors to QuantuMDx Group.
The non-exclusive pact allows QuantuMDx to use the technology worldwide for DNA sequencing and biomarker detection applications. In exchange, QuantuMDx paid Palo Alto, Calif.-based Nanosys an upfront license fee and will make downstream royalty payments.
Further terms of the deal were not disclosed.
QuatuMDx is developing a handheld DNA sequencing technology that will incorporate the nanowires, the firms said in a joint statement. In addition, London-based QuatuMDx plans on developing point-of-care diagnostic instruments.
"Rapid and sensitive biomarker detection, performed at the point of care, at an affordable price point and to standards usually only seen in the referral laboratory will revolutionize care pathways in the developed world and open up a whole new standard of diagnosis in emerging economies," said QuatuMDx CEO Elaine Warburton.